EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Two Targets, One Mission: Heterobivalent Metal‐Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy

Margarida C Sobral, Sandra I Mota, Paulo J Oliveira, Ana M Urbano, António Paulo iD

ChemMedChem · 02.06.2025 · 20 (11)

DOI: 10.1002/cmdc.202500128 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 07.04.2025. Verfasst von Margarida C Sobral und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Interdisciplinary Research, University of Coimbra, 3030-789, Coimbra, Portugal. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 125 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia, COST action CA23156 - European Network, Centro de Investigação em Meio Ambiente, Genética e Oncobiologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is a significant healthcare challenge, associated with considerable mortality and morbidity among men, particularly in developed countries. PCa mortality and morbidity are primarily related to its most advanced form, metastatic castration‐resistant PCa (mCRPC), for which there is presently no cure. Therefore, novel therapeutic approaches to increase mCRPC survival are critically needed. Due to PCa tumor heterogeneity and a complex tumor microenvironment, the efficacy of single‐target radiopharmaceuticals, such as the Food and Drug Administration‐approved [ 177 Lu]Lu‐PSMA‐617, is currently under reassessment. The design and development of PCa dual‐target radiopharmaceuticals have garnered considerable attention, due to their benefits over single‐target counterparts, namely increased therapeutic specificity and efficacy, as well as the ability to overcome the challenge of inconsistent tumor visualization caused by variable receptor expression across diverse lesions, thereby enabling more comprehensive imaging. Several PCa biomarkers are currently being investigated as potential targets for dual‐target radiopharmaceuticals, including prostate‐specific membrane antigen, gastrin‐releasing peptide receptor, integrin α v β 3 receptor, fibroblast activation protein, sigma‐1 receptor, as well as albumin, the radiosensitive cell nucleus, and mitochondria. This review explores recent advancements in heterobivalent metal‐based radiopharmaceuticals for dual targeting in PCa, highlighting their significance in theranostic and personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsProstatic NeoplasmsHumansMaleAnimals

Stichwörter der Autor:innen

dual‐target radiopharmaceuticalpersonalized medicineprostate cancertheranostic

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Institute of Interdisciplinary Research, University of Coimbra, 3030-789, Coimbra, Portugal.
  • CNC-UC, Center for Neuroscience and Cell Biology, University of Coimbra, 3060-197, Cantanhede, Portugal.
  • CIBB, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3000-548, Coimbra, Portugal.
  • Molecular Physical Chemistry R&D Unit, Department of Life Sciences, University of Coimbra, 3000-456, Coimbra, Portugal.
  • Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, 3001-301, Coimbra, Portugal.
  • C2TN -Center for Nuclear Sciences and Technologies, Instituto Superior Técnico, University of Lisboa, 2695-066, Lisboa, Portugal.

ORCID-Profile: António Paulo

Förderung

  • Fundação para a Ciência e a Tecnologia
  • COST action CA23156 - European Network
  • Centro de Investigação em Meio Ambiente, Genética e Oncobiologia

Zitieren

APA

Sobral, M. C., Mota, S. I., Oliveira, P. J., Urbano, A. M., & Paulo, A. (2025). Two Targets, One Mission: Heterobivalent Metal‐Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy. ChemMedChem, 20(11). https://doi.org/10.1002/cmdc.202500128

Vancouver

Sobral MC, Mota SI, Oliveira PJ, Urbano AM, Paulo A. Two Targets, One Mission: Heterobivalent Metal‐Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy. ChemMedChem. 2025;20(11). doi:10.1002/cmdc.202500128

BibTeX
@article{Sobral2025,
  author = {Sobral, Margarida C and Mota, Sandra I and Oliveira, Paulo J and Urbano, Ana M and Paulo, António},
  title = {Two Targets, One Mission: Heterobivalent Metal‐Based Radiopharmaceuticals for Prostate Cancer Imaging and Therapy},
  journal = {ChemMedChem},
  year = {2025},
  volume = {20},
  number = {11},
  doi = {10.1002/cmdc.202500128}
}
Kostenlos starten →